Breast Cancer Clinical Trial

Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

Summary

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥18 years (≥20 years in Taiwan)
Histologically documented advanced/metastatic malignancies

Phase 1 and Phase 2 participants with advanced/metastatic malignancies who have measurable disease (non-measurable disease is allowed only in Phase 1) as determined by RECIST 1.1 will be eligible if, according to the National Comprehensive Cancer Network (NCCN) guidelines, there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options. Additionally, the following specific tumor indications will be enrolled:

Phase 1: Participants with advanced/metastatic malignancies, and preferred indications (non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, cervical, esophageal, gastric, renal, pancreatic, and triple negative breast cancer)
Phase 2 KY1044 single agent: Participants with advanced/metastatic malignancies in indications in which signs of anti-tumor activity (Complete Response (CR), Partial Response (PR) or durable stable disease (SD) with tumor shrinkage that does not qualify for PR) were seen during the dose escalation of KY1044 as single agent

Phase 2 KY1044 in combination with atezolizumab: Participants with advanced/metastatic malignancies in the selected indications below, and/or indications which have shown promising activity in Phase 1:

NSCLC (anti-PD-(L)1 therapy naïve and pre-treated between 1 and 2 prior lines of systemic therapy for advanced disease)
Gastric (anti-PD-(L)1 therapy naïve and pre-treated)
Recurrent and/or metastatic HNSCC (anti-PD-(L)1 therapy naïve and pre-treated between 1 and 2 prior lines of systemic therapy for advanced disease)
Esophageal (anti-PD-(L)1 therapy naïve and pre-treated)
Cervical (anti-PD-(L)1 therapy naïve and pre-treated)
Indications, in which signs of anti-tumor activity has been observed in Phase 1 with KY1044 in combination with atezolizumab
Prior therapy with anti-PD-(L)1 inhibitors is allowed provided any toxicity attributed to prior anti-PD-(L)1-directed therapy did not lead to discontinuation of therapy
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Life expectancy longer than 12 weeks
Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Participants must be willing to undergo a new tumor biopsy at screening, and during therapy on the study

Exclusion Criteria:

Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy, or increasing doses of corticosteroids within the prior 2 weeks of first dose of study treatment
History of severe hypersensitivity reactions to other monoclonal antibodies and/or their excipients
Known presence of neutralizing anti-atezolizumab antibodies (for patients previously treated with atezolizumab)
Having out of range laboratory values: creatinine, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), absolute neutrophil count (ANC), platelet count, hemoglobin

Impaired cardiac function or clinically significant cardiac disease, including any of the following:

Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (New York Heart Association [NYHA] Grade ≥2), uncontrolled hypertension or clinically significant arrhythmia
QTcF >470 msec on screening (electrocardiogram) ECG using Fridericia's formula (QTcF) or congenital long QT syndrome
Acute myocardial infarction or unstable angina pectoris
Known human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection
Malignant disease, other than that being treated in this study
Any medical condition that would, in the Investigator's judgment, prevent participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results
Active autoimmune disease or a documented history of autoimmune disease
Participants previously exposed to anti-PD-(L)1 treatment who are not adequately treated for skin rash or had no replacement therapy for endocrinopathies should be excluded
Participants with a history of drug-induced pneumonitis or current pneumonitis
Systemic steroid therapy or any immunosuppressive therapy. Topical, inhaled, nasal, and ophthalmic steroids are not prohibited
Use of live attenuated vaccines against infectious diseases within 4 weeks of the first dose of study treatment. SARS-CoV-2 vaccines authorized for use by the competent local regulatory health authorities for active immunization to prevent COVID 19 are allowed (unless the vaccine is live or live attenuated) and must be given in accordance with the prevailing immunization guidelines.
Anti-CTLA4, anti-PD-(L)1 treatment within 4 weeks of the first dose of study treatment
Pre-treatment with anti-CTLA4 antibodies in combination with any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathway
Presence of Common Terminology Criteria for Adverse Events version 5 (CTCAE v5) ≥Grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if CTCAE v5 ≥Grade 3) due to prior cancer therapy
Radiotherapy within 2 weeks of the first dose of study treatment, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass. To allow evaluation for response to treatment, participants enrolled in the Phase 2 part must have remaining measurable disease that has not been irradiated
Pregnant or lactating women

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

280

Study ID:

NCT03829501

Recruitment Status:

Recruiting

Sponsor:

Kymab Limited

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Kymab investigational site 1102
New Haven Connecticut, 06510, United States
Kymab investigational site 1108
Orlando Florida, 32806, United States More Info
Kymab Investigator
Contact
Kymab investigational site 1104
Sarasota Florida, 34232, United States More Info
Kymab investigator
Contact
Kymab investigational site 1103
Nashville Tennessee, 37203, United States
Kymab investigator site 1101
Houston Texas, 77030, United States
Kymab investigational site 3901
Milano , , Italy More Info
Kymab investigator
Contact
Kymab investigational site 3903
Milano , , Italy More Info
Kymab Investigator
Contact
Kymab investigational site 3902
Napoli , , Italy More Info
Kymab investigator
Contact
Kymab investigational site 8801
Taipei , , Taiwan More Info
Kymab investigator
Contact
Kymab investigational site 4405
London , , United Kingdom More Info
Kymab investigator
Contact
Kymab investigational site 4402
Manchester , , United Kingdom More Info
Kymab investigator
Contact
Kymab investigational site 4404
Oxford , , United Kingdom More Info
Kymab investigator
Contact
Kymab investigational site 4401
Sutton , , United Kingdom More Info
Kymab investigator
Contact

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

280

Study ID:

NCT03829501

Recruitment Status:

Recruiting

Sponsor:


Kymab Limited

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.